⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Brise Pharmaceuticals and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Brise Pharmaceuticals
↗Shanghai, China
Brise Pharmaceuticals is a clinical-stage biopharmaceutical company headquartered in China, dedicated to developing innovative and highly differentiated analgesic treatments for severe pain conditions. The company focuses on addressing significant unmet needs in areas such as migraine, chronic inflammatory pain, and neuropathic pain.
Founded in 2021 by a team of industry veterans, Brise Pharma leverages genetic and pathological evidence to select optimal drug targets and modalities. Their approach combines in-house research with strategic collaborations to advance a pipeline of small molecules and monoclonal antibodies through preclinical and clinical development.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Founded:2021
Ownership:private
Status:operating
FUNDING
Stage:Series A
Total Raised:$71.9M
Investors:Qiming Venture Partners, Shunxi Fund, INCE Capital, Proxima Ventures, BioTrack Capital, Sherpa Healthcare Partners
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 2
Modalities:Small molecule, Monoclonal antibody
Active Trials:1
Trial Phases:Phase 1: 1 | Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Crystal Formulation Services (CDMO partner for drug product development)
COMPETITION
Position:Emerging
Competitors:Jazz Pharmaceuticals, argenx, Sana Biotechnology, Heron Therapeutics
LEADERSHIP
Key Executives:
Eric Liu - Chief Medical Officer
LINKS
Website:brisepharma.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Brise Pharmaceuticals. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.